Related Experiment Video
Updated: Aug 9, 2026
Visualizing Antigen Specific CD4+ T Cells using MHC Class II Tetramers
Published on: March 6, 2009
Soluble CD8 stabilizes the HLA class I molecule by promoting beta2M exchange: analysis in real-time
C L Morgan1, C P Price, S B Cohen
1Anthony Nolan Research Institute, The Royal Free Hospital, London, UK. clmorgan@rfhsm.ac.uk
Insights
Soluble CD8 (sCD8) stabilizes HLA class I molecules, potentially blocking T cell activation. This suggests sCD8 may have an immunosuppressive role and could be a target for new therapies.
Area of Science:
- Immunology
- Molecular Biology
- Biochemistry
Background:
- Soluble CD8 (sCD8) is secreted by activated CD8+ cytotoxic T lymphocytes (CTLs).
- The precise immunological function of sCD8 remains largely undefined.
- Understanding sCD8's role is crucial for immunology and potential therapeutic interventions.
Purpose of the Study:
- To investigate the influence of sCD8 on HLA class I interactions.
- To elucidate the mechanism by which sCD8 affects HLA class I stability.
- To explore the potential immunosuppressive role of sCD8.
Main Methods:
- Real-time analysis using an optical biosensor.
- Kinetic analysis of sCD8 binding to HLA-A2.
- Assessment of beta2-microglobulin (beta2m) exchange and complex stabilization.
Main Results:
- sCD8 binding to HLA-A2 promotes beta2m exchange, stabilizing the complex.
- sCD8 significantly increased the affinity of HLA-A2 for beta2m.
- sCD8 demonstrated a stabilizing influence on HLA class I, even with exogenous peptides present.
Conclusions:
- The sCD8:HLA class I complex is likely stabilized at the cell surface, resisting degradation.
- sCD8 binding to HLA class I may block the binding site for CTL-bound CD8, inhibiting T cell activation.
- sCD8 exhibits potential immunosuppressive properties, offering a possible avenue for novel immunosuppressive therapies.
Abstract:
Human soluble CD8 (sCD8) is secreted by activated CD8+/- cytotoxic T lymphocytes (CTLs). The immunological role of sCD8 is poorly defined, however. We have studied the influence of sCD8 on HLA class I interactions by real-time analysis. Using an optical biosensor we demonstrated that the binding of sCD8 to HLA-A2 promotes exchange of beta2-microglobulin (beta2m) in order to stabilize the complex. Kinetic analysis showed that sCD8 significantly increased the affinity (K(A)) of HLA-A2 for immobilized human beta2m; from 1.14 +/- 0.04 x 10(9) M(-1) in its absence, to 2.18 +/- 0.21 x 10(9) M(-1) following preincubation with sCD8. This suggests that the sCD8:HLA class I complex is unlikely to be degraded at the cell surface. Even in the presence of exogenous peptide (HLA-A2 specific or nonspecific), sCD8 has a stabilizing influence on the HLA class I molecule. These findings point to an immunosuppressive role for sCD8, because the binding of sCD8 to HLA class I would block the binding site for CTL-bound CD8 and, therefore, interfere with T cell activation and proliferation. This may have particular significance in pathological situations where elevated levels of sCD8 are found in extracellular fluids, and sCD8 may provide an alternative approach for immunosuppressive therapy.
